未登录

M

Mark Bensink

university college london

H指数:21

被引数:1,529

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Experience with Anti-CGRP Pathway Monoclonal Antibodies in a Large United States Healthcare Plan: Results of the Migraine Signature Study

真实世界中使用抗CGRP通路单克隆抗体在美国大型医疗计划中的经验：偏头痛标志研究的成果

Neurology and Therapy

IF4.8

2025-12-170

OAAI

The humanistic burden of focal segmental glomerulosclerosis on patients and care-partners in the United States

QUALITY OF LIFE RESEARCH

IF2.7

2025-04-010

OAAI

Epidemiology and burden of focal segmental glomerulosclerosis among United States Veterans: An analysis of Veteran's Affairs data

美国退伍军人中局灶节段性肾小球硬化的流行病学及疾病负担：一项退伍军人事务部数据分析

IF2.6

2024-12-130

OA

The humanistic burden of immunoglobulin A nephropathy on patients and care-partners in the United States

QUALITY OF LIFE RESEARCH

IF2.7

2024-10-260

OAAI

Changes in use of acute and preventive medications for migraine after erenumab initiation over 12months: A United States retrospective cohort study

IF4

2024-09-090

OAAI

Cardiovascular, Kidney Failure, and All-Cause Mortality Events in Patients with FSGS in a US Real-World Database

IF3

2024-05-150

OAAI

Kidney Failure Events, Cardiovascular Disease Events, and All-Cause Mortality in Patients with IgA Nephropathy in a Real-World Database

IF3

2024-02-071

OAAI

Kidney Failure Attributed to Immunoglobulin A Nephropathy: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden

KIDNEY MEDICINE

IF3.4

2024-02-010

OAAI

Kidney Failure Attributed to Focal Segmental Glomerulosclerosis: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden

KIDNEY MEDICINE

IF3.4

2024-02-011

OAAI

Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway

JOURNAL OF HEADACHE AND PAIN

IF7.9

2023-11-092

OAAI

Impact of Proteinuria and Kidney Function Decline on Health Care Costs and Resource Utilization in Adults With IgA Nephropathy in the United States: A Retrospective Analysis

KIDNEY MEDICINE

IF3.4

2023-09-015

OAAI

Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials

IF4

2022-02-083

PRE

Real-World Treatment Profiles, Clinical Outcomes, and Healthcare Resource Utilization of Patients with Migraine Prescribed Erenumab: A Multicenter Chart-Review Study of US Headache Centers

NEUROLOGY AND THERAPY

IF4.8

2021-04-1522

OAAI

Erenumab patient characteristics, medication adherence, and treatment patterns in the United States

IF4

2021-02-1616

PREAI

United States Patients' Perspective of Living With Migraine: Country-Specific Results From the Global My Migraine Voice Survey

IF4

2020-05-0529

OAAI

Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study

IF3.4

2019-08-0914

OAAI

BREAST CANCER PATIENT PREFERENCE AND WILLINGNESS TO PAY FOR GRANULOCYTE COLONY-STIMULATING FACTORS (G-CSF)

VALUE IN HEALTH

IF6

2019-05-011

OAAI

THE LONG-TERM SOCIAL VALUE OF BETTER TARGETING G-CSF THERAPY TO CANCER PATIENTS AT RISK OF FEBRILE NEUTROPENIA

VALUE IN HEALTH

IF6

2018-05-010

OAAI

A TIME-MOTION OBSERVATIONAL STUDY OF CLINIC STAFF: ADMINISTRATION OF PE GFIL GRASTIM PRIMARY PROPHYLAXIS VIA NEXT-DAY MANUAL INJECTION AND ON-BODY INJECTOR (OBI)

VALUE IN HEALTH

IF6

2018-05-011

OAAI

Comparative Effectiveness Research: A Roadmap for Physical Activity and Lifestyle

MEDICINE & SCIENCE IN SPORTS & EXERCISE

IF3.9

2015-08-012

OAAI